Mizuho Securities on Acadia Pharmaceuticals (ACAD): 'Adequacy and Reliability of Data are Key Risks to Upcoming AdComm'
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan reiterated a Neutral rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
